13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001792126
Total reported value
$2.3B
$2.3B
55 檔
11.5%
The Q3 2024 SEC filing reveals that Logos Global Management LP held a total portfolio value of $2.3B, covering 55 public equity positions.
Logos Global Management LP executed strategic sector rebalancing during Q3 2024, establishing 15 new positions while fully exiting 13 holdings and trimming 20 positions.
In terms of portfolio concentration, the top 5 core holdings (including IDYA, GPCR, RVMD) accounted for 11.5% of total reported equity market value during Q3 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | IDYA | Ideaya Biosciences Inc | Stock-Other | 7.18% | -0.93% | +23.53% | |
| 2 | GPCR | Structure Therapeutics Inc | Stock-Other | 5.92% | -0.04% | -19.35% | |
| 3 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 5.87% | -4.07% | — | |
| 4 | IRON | Disc Medicine Inc | Stock-Other | 4.96% | +0.97% | +1.08% | |
| 5 | JANX | Janux Therapeutics Inc | Stock-Other | 4.90% | -0.69% | EXIT | |
| 6 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 4.13% | -0.66% | — | |
| 7 | PCVX | Vaxcyte Inc | Stock-Other | 3.70% | -0.87% | EXIT | |
| 8 | IMVT | Immunovant Inc | Stock-Other | 3.38% | -0.23% | +91.30% | |
| 9 | CLDX | Celldex Therapeutics Inc | Stock-Other | 3.30% | +2.65% | — | |
| 10 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.29% | +0.61% | -32.04% | |
| 11 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 3.24% | — | +150.00% | |
| 12 | ERAS | Erasca Inc | Stock-Other | 3.21% | +0.57% | +84.75% | |
| 13 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 3.11% | — | -58.33% | |
| 14 | ✓ | Merus N V | Stock-Other | 3.10% | — | -32.35% | |
| 15 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 2.48% | — | — | |
| 16 | AKRO | Akero Therapeutics Inc | Stock-Other | 2.48% | — | — | |
| 17 | DSGN | Design Therapeutics Inc | Stock-Other | 2.45% | +0.83% | -16.19% | |
| 18 | VERA | Vera Therapeutics Inc | Stock-Other | 2.38% | +4.06% | NEW | |
| 19 | COGT | Cogent Biosciences Inc | Stock-Other | 2.33% | +1.50% | NEW | |
| 20 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.28% | -2.88% | EXIT | |
| 21 | BCAX | Bicara Therapeutics Inc | Stock-Other | 2.20% | — | — | |
| 22 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 2.02% | — | -76.92% | |
| 23 | ANNX | Annexon Inc | Stock-Other | 1.66% | +0.37% | NEW | |
| 24 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.66% | — | — | |
| 25 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.36% | -1.02% | -16.81% | |
| 26 | BEAM | Beam Therapeutics Inc | Stock-Other | 1.32% | — | — | |
| 27 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.30% | — | — | |
| 28 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 1.22% | — | — | |
| 29 | YMABUSD | Y-mabs Therapeutics Inc | Stock-Other | 1.14% | — | — | |
| 30 | ARVN | Arvinas Inc | Stock-Other | 1.06% | — | — | |
| 31 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.99% | +0.08% | -1.79% | |
| 32 | NUVL | Nuvalent Inc-a | Stock-Other | 0.83% | — | -61.54% | |
| 33 | CMPS | Compass Pathways PLC | Stock-Other | 0.79% | +1.37% | NEW | |
| 34 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.68% | — | — | |
| 35 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.65% | — | -7.14% | |
| 36 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.63% | — | -65.22% | |
| 37 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.62% | +1.17% | -39.62% | |
| 38 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.59% | — | — | |
| 39 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.58% | — | — | |
| 40 | HELP | Cybin Inc | Stock-Other | 0.58% | +0.21% | NEW | |
| 41 | ✓ | Engene Holdings Inc | Stock-Other | 0.57% | — | -33.33% | |
| 42 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.55% | -0.06% | — | |
| 43 | LCTX | Lineage Cell Therapeutics In | Stock-Other | 0.49% | — | +6.38% | |
| 44 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.44% | — | — | |
| 45 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.39% | — | -86.45% | |
| 46 | ATYR | Atyr Pharma Inc | Stock-Other | 0.38% | — | -33.33% | |
| 47 | NXTCEUR | Nextcure Inc | Stock-Other | 0.37% | — | — | |
| 48 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.32% | — | — | |
| 49 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 0.23% | — | — | |
| 50 | ✓ | Stock-Other | 0.22% | — | +46.37% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PCVX | Vaxcyte Inc | +3.7% | NEW | New buy |
| 2 | CLDX | Celldex Therapeutics Inc | +3.3% | NEW | New buy |
| 3 | LKFT | Lakefront Biotherapeutic-adr | +2.5% | NEW | New buy |
| 4 | IDYA | Ideaya Biosciences Inc | +2.4% | +23.53% | Add |
| 5 | JANX | Janux Therapeutics Inc | +2.4% | +33.33% | Add |
| 6 | COGT | Cogent Biosciences Inc | +2.3% | NEW | New buy |
| 7 | CYTK | Cytokinetics Inc | +2.3% | NEW | New buy |
| 8 | BCAX | Bicara Therapeutics Inc | +2.2% | NEW | New buy |
| 9 | IMVT | Immunovant Inc | +2.2% | +91.30% | Add |
| 10 | RVMD | Revolution Medicines Inc | +2.1% | — | Unchanged |
| 11 | ERAS | Erasca Inc | +2.1% | +84.75% | Add |
| 12 | IONS | Ionis Pharmaceuticals Inc | +2.1% | +150.00% | Add |
| 13 | TVTX | Travere Therapeutics Inc | +1.7% | NEW | New buy |
| 14 | IRON | Disc Medicine Inc | +1.6% | +1.08% | Add |
| 15 | OLMA | Olema Pharmaceuticals Inc | +1.3% | — | Unchanged |
| 16 | BEAM | Beam Therapeutics Inc | +1.3% | NEW | New buy |
| 17 | EWTX | Edgewise Therapeutics Inc | +1.3% | NEW | New buy |
| 18 | BCYC | Bicycle Therapeutics Plc-adr | +1.2% | NEW | New buy |
| 19 | YMABUSD | Y-mabs Therapeutics Inc | +1.1% | NEW | New buy |
| 20 | DSGN | Design Therapeutics Inc | +1.1% | -16.19% | Trim |
| 21 | ARVN | Arvinas Inc | +1.1% | NEW | New buy |
| 22 | GPCR | Structure Therapeutics Inc | +1% | -19.35% | Trim |
| 23 | AKRO | Akero Therapeutics Inc | +1% | — | Unchanged |
| 24 | ORKA | Oruka Therapeutics Inc | +0.7% | NEW | New buy |
| 25 | HELP | Cybin Inc | +0.6% | NEW | New buy |
| 26 | OCUL | Ocular Therapeutix Inc | +0.5% | -32.04% | Trim |
| 27 | TRVI | Trevi Therapeutics Inc | +0.3% | -1.79% | Trim |
| 28 | ELVN | Enliven Therapeutics Inc | +0.2% | -16.81% | Trim |
| 29 | ARTV | Artiva Biotherapeutics Inc | +0.2% | NEW | New buy |
| 30 | CMPS | Compass Pathways PLC | +0.2% | — | Unchanged |
| 31 | CATBUSD | Astria Therapeutics Inc | +0.2% | — | Unchanged |
| 32 | LCTX | Lineage Cell Therapeutics In | +0.1% | +6.38% | Add |
| 33 | RAPP | Rapport Therapeutics Inc | +0.1% | — | Unchanged |
| 34 | AVU0 | Adverum Biotechnologies Inc | +0.1% | — | Unchanged |
| 35 | ✓ | +0.1% | +46.37% | Add | |
| 36 | NXTCEUR | Nextcure Inc | +0.1% | — | Unchanged |
| 37 | RCKT | Rocket Pharmaceuticals Inc | 0% | -7.14% | Trim |
| 38 | AVTX | Avalo Therapeutics Inc | 0% | — | Unchanged |
| 39 | IOBTQ | Io Biotech Inc | 0% | — | Unchanged |
| 40 | ATYR | Atyr Pharma Inc | — | -33.33% | Trim |
| 41 | NUVB-WS | Nuvation Bio Inc -cw27 | — | EXIT | Sold out |
| 42 | BOLD | Boundless Bio Inc | 0% | -50.00% | Trim |
| 43 | ALLKGUSD | Allakos Inc | 0% | — | Unchanged |
| 44 | NMRA | Neumora Therapeutics Inc | -0.1% | -66.67% | Trim |
| 45 | DYN | Dyne Therapeutics Inc | -0.1% | -39.62% | Trim |
| 46 | FULC | Fulcrum Therapeutics Inc | -0.2% | — | Unchanged |
| 47 | RNAC | Cartesian Therapeutics Inc | -0.2% | EXIT | Sold out |
| 48 | APLT | Applied Therapeutics Inc | -0.2% | EXIT | Sold out |
| 49 | ANNX | Annexon Inc | -0.2% | -45.83% | Trim |
| 50 | ✓ | Engene Holdings Inc | -0.3% | -33.33% | Trim |
According to official SEC Form 13F filings, Logos Global Management LP reported a total U.S. public equity portfolio value of $2.3B across 55 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
PCVX
市值: $34.3M
Top Position Liquidated / Trimmed
XBI
前期市值: $185.4M
During Q3 2024, Logos Global Management LP's top holdings by market value included IDYA (7.2%)、GPCR (5.9%)、RVMD (5.9%). The largest single position, IDYA, represented 7.2% of total portfolio value.
In Q3 2024, Logos Global Management LP made 56 total portfolio adjustments, initiating 15 new buys, adding to 8 positions, trimming 20 holdings, and fully liquidating 13 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.